risk of lamotrigine-induced rash, and necessitates reduced dosing due to the interaction of these drugs (Pellock, 1999). Lamotrigine (Lamictal) is the first FDA-approved therapy since lithium for maintenance treatment of bipolar I disorder (GlaxoSmithKline, 2003). While traditional anticonvulsant drugs are primarily antimanics, lamotrigine is most effective in the treatment and prophylaxis